iShares Gold Trust vs Zimmer Biomet Holdings Inc — how do they compare? iShares Gold Trust trades at $76.32, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals.
| IAU | ZBH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $107.71 |
52-Week Low | $61.62 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.
The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Trailing returns across standard periods
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →